Progression-free survival of bcl-2–negative diffuse large B-cell lymphomas in 16 HIV-positive (AIDS-related lymphoma) and in 17 HIV-negative (historical group) patients who were similarly treated with DA-EPOCH. Progression-free survival probabilities are 94% in the HIV-positive patients and 82% in the HIV-negative patients, at their respective median potential follow-up times of 53 months and 69 months.